<DOC>
	<DOCNO>NCT02243228</DOCNO>
	<brief_summary>The purpose study evaluate inhale granulocyte-macrophage colony stimulate factor delay increase alveolar-arterial oxygen difference , compare treatment , adult patient mild-to-moderate autoimmune pulmonary alveolar proteinosis China two-year period .</brief_summary>
	<brief_title>Inhalation Granulocyte-macrophage Colony-stimulating Factor ( GM-CSF ) Autoimmune Pulmonary Alveolar Proteinosis ( PAP )</brief_title>
	<detailed_description>Autoimmune pulmonary alveolar proteinosis ( PAP , previously know idiopathic PAP ) rare interstitial lung disease elicit formation autoantibody neutralize activity granulocyte-macrophage colony-stimulating factor ( GM-CSF ) decrease macrophage clearance surfactant . Currently , standard treatment strategy PAP whole lung lavage ( WLL ) ，which invasive limitation . Inhaled GM-CSF therapy become new option PAP patient effectiveness safety , convenient way patient reluctant operation well . We plan prospectively evaluate inhaled granulocyte-macrophage colony stimulate factor would delay increase alveolar-arterial oxygen difference ( A-aDO2 , sensitive factor evaluate APAP5 ) , compare placebo , patient mild-to-moderate autoimmune pulmonary alveolar two-year period . A total 42 subject APAP meet inclusion criterion enrol Peking Union Medical College Hospital Nanjing Drum Tower Hospital . After observe APAP patient 3 month rule patient resolve spontaneously , participant undergo randomization ( random number table ) stratify two different group DSS . Then treat GM-CSF ( use nebulizer , 150ug bid ) every week treatment 6 month , follow outpatient basis 2 week , 1 , 3 , 6 , 9 , 12 , 15 , 18 , 21 24 month initiation therapy .</detailed_description>
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Accessible population : Adult patient mildtomoderate autoimmune pulmonary alveolar without spontaneous remission enrol Peking Union Medical College Hospital Nanjing Drum Tower Hospital . Adult autoimmune PAP subject include : 1 ) positive PAS stain BALF lung biopsy ; 2 ) high level serum antiGMCSF antibody ( &gt; 2.39ug/ml , cutoff point hospital ) ; 3 ) age 18 year old ; 4 ) exclude hereditary secondary PAP . Able give write informed consent comply requirement study . Patients eligible whole lung lavage ( WLL ) , decide clinician . Eligibility GMCSF inhalation : 1 ) Disease severity score ( DSS ) 13 ; 2 ) No treatment GMCSF therapy WLLin 3 month prior enrollment . Definition DSS2 : 1 , symptom PaO2 &gt; =70mmHg；2 , PaO2 &gt; =70mmHg symptoms；3 , PaO2 &gt; =60 &lt; 70mmHg ; 4 , PaO2 &gt; =50 &lt; 60mmHg ; 5 , PaO2 &lt; 50mmHg . Patients observe 3 month APAP patient resolve spontaneously exclude study . PAP result another condition ( e.g . occupational exposure silica , underlie HIV , respiratory infection , myeloproliferative disorder leukaemia ) ; A normal lowtitre serum antiGMCSF antibody ( ≤2.39ug/ml ) ; History severe allergic anaphylactic reaction humanize murine monoclonal antibodies； Chronic lung disease associate already exist respiratory failure ( pulmonary emphysema fibrosis ) ; Other serious medical condition , opinion investigator , would make patient unsuitable study . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>granulocyte-macrophage colony stimulate factor ( GM-CSF )</keyword>
	<keyword>Autoimmune pulmonary alveolar proteinosis ( PAP )</keyword>
</DOC>